Exicure, Inc. (XCUR)

$2.22

-0.08 (-3.48%)
Rating:
Recommendation:
-
Symbol XCUR
Price $2.22
Beta 1.269
Volume Avg. 0.63M
Market Cap 11.016M
Shares () -
52 Week Range 1.49-43.5
1y Target Est -
DCF Unlevered XCUR DCF ->
DCF Levered XCUR LDCF ->
ROE -232.29% Strong Sell
ROA -90.22% Strong Sell
Operating Margin -
Debt / Equity 1194.68% Strong Buy
P/E -
P/B 2.01 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest XCUR news


Dr. David Giljohann
Healthcare
Biotechnology
NASDAQ Capital Market

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.